Results 81 to 90 of about 55,807 (330)

The efficacy and safety of sodium‐glucose cotransporter 2 inhibitors in patients aged over 80 years with heart failure

ESC Heart Failure, EarlyView.
Abstract Aims Sodium‐glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) have demonstrated effectiveness in reducing cardiovascular death and heart failure hospitalization (HFH). However, the efficacy and safety of SGLT2 inhibitors in elderly patients with poor general status, such as very low bodyweight or low nutritional status, who are not included ...
Kenji Nakano, Kenji Kanenawa, Akihiro Isotani, Takashi Morinaga, Kaori Yamamoto, Norihisa Miyawaki, Euihong Ko, Miho Nakamura, Yuichi Tanaka, Kenichi Ishizu, Toru Morofuji, Masaomi Hayashi, Masato Fukunaga, Makoto Hyodo, Shinichi Shirai, Kenji Ando   +15 more
wiley   +1 more source

Euglycemic Diabetic Ketoacidosis in a Patient Post Cardiac Surgery Receiving Continuous Renal-Replacement Therapy

Annals of Internal Medicine: Clinical Cases, 2023
Euglycemic diabetic ketoacidosis is an often-underrecognized endocrine emergency. We highlight an unusual presentation of euglycemic diabetic ketoacidosis in a patient with a history of hypertension, type 2 diabetes mellitus, and stage 3b chronic kidney ...
Walter Yaw Agyeman, Inemesit Akpan, Kwasi Opare-Addo, Saheed Soleye, Alfred Solomon   +4 more
doaj   +1 more source

Variable Weights Neural Network For Diabetes Classification [PDF]

arXiv, 2021
As witnessed in the past year, where the world was brought to the ground by a pandemic, fighting Life-threatening diseases have found greater focus than ever. The first step in fighting a disease is to diagnose it at the right time. Diabetes has been affecting people for a long time and is growing among people faster than ever. The number of people who
arxiv  

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
wiley   +1 more source

HealthEdge: A Machine Learning-Based Smart Healthcare Framework for Prediction of Type 2 Diabetes in an Integrated IoT, Edge, and Cloud Computing System [PDF]

arXiv, 2023
Diabetes Mellitus has no permanent cure to date and is one of the leading causes of death globally. The alarming increase in diabetes calls for the need to take precautionary measures to avoid/predict the occurrence of diabetes. This paper proposes HealthEdge, a machine learning-based smart healthcare framework for type 2 diabetes prediction in an ...
arxiv  

An audit of the management of diabetic ketoacidosis at St Luke’s Hospital [PDF]

, 2008
Aim: To perform an audit of the protocol used in the management of patients with Diabetic Ketoacidosis, in St Lukes Hospital. Methods: Patients admitted with `Diabetes Ketoacidosis', between 14th August 2004 and 14th August 2005, were identified from the
Abela, Alexia-Giovanna, Azzopardi, Joseph, Calleja, Neville, Debono, Miguel, Magri, Caroline Jane, Vassallo, Josanne   +5 more
core  

Novel diabetes drugs and the cardiovascular specialist [PDF]

, 2017
Recently, treatment with 2 newer classes of type 2 diabetes drugs were found to reduce events in patients with diabetes and cardiovascular (CV) disease, a group common in cardiology clinics.
Januzzi Jr., James L., Petrie, Mark C., Sattar, Naveed, Zinman, Bernard   +3 more
core   +1 more source

Outcomes of Acute Invasive Fungal Rhinosinusitis Patients Treated with Retrobulbar Amphotericin B Injections versus Orbital Exenteration

International Forum of Allergy &Rhinology, EarlyView.
Jakob L. Fischer, Nikitha Kosaraju, Katherine M. Lucarelli, Christine R. Wells, Connie M. Sears, Reem Karmouta, Ashley S. Shirriff, Maxwell Weng, Jeffrey D. Suh, Jivianne T. Lee, Daniel M. Beswick, Daniel B. Rootman, Marilene B. Wang   +12 more
wiley   +1 more source

Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART‐FID

European Journal of Heart Failure, EarlyView.
Changes in serum phosphate levels over time with ferric carboxymaltose (FCM) in a randomized, double‐blind, prospective substudy of HEART‐FID assessing the following outcomes: serum phosphate, 1,25 dihydroxyvitamin D, 25‐hydroxyvitamin D levels and plasma levels of intact parathyroid hormone during 6 months subsequent to FCM infusion.
Nina Nouhravesh, Jyotsna Garg, Frank W. Rockhold, Carmine G. De Pasquale, Eileen O'Meara, Gregory D. Lewis, Javed Butler, Josephine Harrington, Justin A. Ezekowitz, Piotr Ponikowski, Richard W. Troughton, Yee Weng Wong, Nicole Blackman, Syed Numan, Robert Adamczyk, Adrian F. Hernandez, Robert J. Mentz   +16 more
wiley   +1 more source

Immune checkpoint inhibitor-associated diabetic ketoacidosis and insulin-dependent diabetes: a case report

Journal of Medical Case Reports
Background Immunotherapy, including the use of immune checkpoint inhibitors such as nivolumab, is increasingly common in cancer treatment and can lead to various immune-related adverse effects, including rare cases of diabetic ketoacidosis.
Yungee Jung, Anthony Lau, Joseph Bednarczyk   +2 more
doaj   +1 more source